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Supplementary Online Material 
Summary Equations 
The system is described by a set of nonlinear ordinary differential equations of the form: 
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Artemisinin is represented as a and piperaquine as b with ACT being ab. 
The sets R, D and G refer to the categories of resistance, drug activity and intervention strategy 
respectively. The arrays ν  (recovery from infection under the action of the drugs i.e. recovery 
rates), τ  (rate of drug acquisition i.e. treatment rates) and f (intervention treatment strategies) 
depend on the nature of the intervention strategies and combinations of drugs. 
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The arrays X and Y define the dynamics of the sequential loss of drug effect where ax is the 
duration of ACT treatment plus the time post treatment  to sub therapeutic levels of artesunate 
and bx is the duration of ACT treatment plus the time post treatment to sub therapeutic levels of 
the partner drug. T represents the transpose function on the associated vector. 
 
This deterministic model was also rewritten as two stochastic models; one population based and 
another individual based. All three models used the same structure and parameters. The 
population dynamic stochastic model was a set of difference equations based on the Euler 
approximation of the corresponding differential equations as the means of a set of Poisson 
distributions from which the value of each variable was sampled at each time step. For the 
individual based model, a population of individuals was generated with a list of states which 
defined the variables of the corresponding deterministic model. The individuals change from one 
state to another with probabilities defined by the parameters of the corresponding deterministic 
model apart from the transmission parameter. In this instance, transition from uninfected to 
blood stage was modeled as the probability of a susceptible individual receiving an infectious 
bite from a mosquito which had previously bitten an infected individual chosen at random. These 
two stochastic models produced very similar results and 200 runs of the population based model 
were used to generate the results given in the paper. 
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Supplementary tables 
Table S1. Assumptions.  
Assumption 
Reasoning for likely effect on 
time to eradication if true 
Justification for making the assumption 
 
Likely to increase time to eradication of artesunate resistance* 
No immunity to malaria 
i.e. transmission rate is 
low. 
Infection more likely to result in 
symptoms therefore more people 
seeking and receiving treatment. 
Transmission rates in Western Cambodia 
are generally much lower than in sub-
Saharan Africa, for example [1]. There are 
small focal areas with higher rates and we 
plan to explore this with a spatially 
heterogeneous model when sufficient data 
becomes available. 
Low (0 to 5%) survival 
disadvantage (fitness 
cost) for artesunate 
resistant parasites 
compared to drug 
sensitive parasites. 
More robust resistant parasites are 
harder to eradicate. 
The relative viability of malaria parasites 
with artesunate resistant phenotypes is not 
known, although survival disadvantage, if it 
exists at all, is likely to be minimal [2]. 
No mortality due to 
malaria. 
Those people with resistant 
infections are less likely to respond 
to treatment and therefore more 
likely to die, thus removing them 
from the transmitting population. 
In reality the proportion of malaria infections 
which are fatal in this region is low, around 
0.6% [3] 
 
Artesunate is the only 
available effective 
treatment before 2009. 
Artesunate would be less likely to 
cure artemisinin-resistant infections 
than non-artemisinin drugs, if 
Although co-blistered artesunate and 
mefloquine has been the official first-line 
drug since 2000, in reality a wide range of 
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available. treatments is available over the counter in 
Cambodia. The majority receive artesunate 
monotherapy whereas most of the other 
treatments are inadequate (resistant 
parasites/wrong dose/wrong duration) to 
cure infection [4]. 
Rate of resistance to 
artesunate is increasing 
exponentially at the time 
of intervention. 
If the rate of resistance was stable 
or decreasing then infection would 
be easier to eradicate. 
Expert opinion in the absence of historical 
data. 
Rate of resistance to 
piperaquine is stable at 
the time of intervention. 
If the rate of piperaquine resistance 
was increasing then piperaquine 
would take longer to eradicate 
infection. 
Expert opinion in the absence of historical 
data. 
 
Likely to decrease time to eradication of artesunate resistance* 
No pre-existing 
resistance to DHA / 
piperaquine ACT, only 
to artesunate and 
piperaquine alone. 
If there are infections resistant to 
ACT then these will be even harder 
to cure than those with resistance 
to the individual drugs. 
No evidence for pre-existing resistance to 
ACT has ever been found. 
No resistance to 
atovaquone, proguanil 
or primaquine. 
Interventions using these drugs will 
have maximal effectiveness if there 
is no resistance. 
Rates of resistance to each of these drugs 
are thought to be low in this region. 
Recombination between 
drug resistant mutants 
not frequent enough to 
have a significant effect 
Recombination has the potential to 
generate parasites resistant to both 
components of ACT. 
There is no strong evidence for frequent 
recombination combining drug resistance 
mutations in malaria. 
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in the model timescale. The genetics of resistance to artemisinins 
and piperaquine are unknown therefore a 
model of this would be conjectural 
 
If the inheritance of resistance to either of 
these drugs is polygenic, e.g. acquired 
incrementally by the acquisition of a series 
of mutations, then recombination would 
decrease the strength and prevalence of 
resistance. 
 
No spatial heterogeneity 
i.e. transmission, 
coverage of 
interventions, access to 
health services, etc. 
Infection in high transmission areas 
is harder to eradicate therefore 
taking longer. 
This is potentially important for planning 
interventions but it is not known to what 
degree this exists in Western Cambodia.  
 
In the absence of data about most spatially 
heterogeneous parameters we felt their 
incorporation at this stage was premature. 
 
We are in the ongoing process of gathering 
data to allow the incorporation of realistic 
spatial heterogeneity into the next stage of 
this model. 
 
No migration. 
People do not continue to introduce 
new resistant parasites. 
To maintain simplicity. 
 
In-migration of sensitive infections would 
accelerate the elimination of resistance. In-
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migration of resistant infections would slow 
it. Out-migration of resistant infections 
would mean control/elimination efforts 
would have to include these areas also in 
order to achieve elimination. 
 
As we are modeling containment strategies 
for the only area where artesunate 
resistance has been identified, Inmigration 
of resistant infections is not relevant. 
* The first 6 assumptions are all likely to increase the time to eradication of resistance, whereas the other 
5 assumptions probably decrease the time to eradication, for the reasons given. Hence this model is 
probably conservative overall. 
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Table S2. Parameters. These were based largely on expert opinion of the co-authors and were 
derived from published data, where available, as stated below. For those parameters for which a 
range of values is given, this reflects uncertainty of their true value.  For these parameters, the 
underlined values were used to generate the plots and results stated in the text and the ranges 
were used in the sensitivity analysis.  
 
Symbol 
 
Description 
 
Value 
 
Source 
Population demographics 
N0 Total population size  3.2*10
6 
[5] 
µ Birth rate = death rate 15/1000/year [6] 
  
Prevalence of malaria in population 
pBI Proportion of population with slide positive 
malaria infection in high transmission 
season in 2009 
 
0.074 [1] 
pinf Proportion of population with infectious 
blood stage infection at time=0 
0.16 (the value 
required to give 
pBI ~ 0.074) 
 
pa Proportion of malaria infections that are 
resistant to artesunate in 2008 
0.1 Expert opinion 
 
pb 
 
Proportion of malaria infections that are 
 
0.05 
 
Expert opinion 
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resistant to piperaquine in 2009 
 
Natural history of malaria infection 
δ Natural recovery rate from infection 
 
1/200 - 1/60 days
-1
 [7-12] 
γ Rate of liver stage becoming blood stage 1/5 days
-1
 [7-9] 
 
σ 
 
Rate of blood stage becoming gametocytes 
 
1/15 days
-1
 
 
[13,14] 
 
amp 
 
Amplitude of seasonal variation of 
transmission 
 
0.67 
 
[15] 
 
Rates of initiation and proportions of population receiving drug treatment 
  
Artemisinin monotherapy 
starta Year of introduction of artemisinin 
monotherapy 
1975 Expert opinion 
 = ai1  
   = ai2 
Rate of starting artemisinin monotherapy  1/16 infected people 
per day 
[4] 
 
propRxam 
 
Proportion of infected population who 
receive antimalarials 
 
 
0.63 
 
[4] 
propa Proportion of antimalarials constituting 
artemisinin monotherapy before an 
0.4 [4] 
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intervention 
 
adha Proportion of infected population that take 
full 7 day course of artemisinin 
monotherapy 
 
0.2 [4] 
propRxa Proportion of infected population that take 
effective artemisinin monotherapy = 
propRxam*propa*adha  
0.05 = propRxam*propa 
*adha 
  
Interventions 
ab = ab1 
       = ab2 
Rate of starting ACT for treatment 
 
 
16 infected people per 
day 
[4] 
1 = 2 = 3 Rate of reaching maximum coverage for 
MDA or MSAT 
 
1/0.25 years
-1
 Expert opinion 
covi1 = covi2 
= covi3 
 
covab 
 
 
psab 
 
 
Maximum coverage of MDA or MSAT 
 
 
Maximum coverage with ACT after 
replacement of artemisinin monotherapy  
 
Proportion of vendors selling modern drugs 
that could sell ACT 
 
0.8 
 
 
0.6 
 
 
0.85 
 
 
Expert opinion 
 
 
Expert opinion 
 
 
[4] 
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adhab 
= adhvg 
 
 
propRxi1  
= propRxi2 
= propRxi3 
 
 
pab 
 
 
 
Adherence to 3 day course of ACT =  
Adherence to 3 days of atovaquone/ 
proguanil 
 
Proportion that receive full 3 day course of 
MDA/MSAT  
 
 
 
Proportion that receive full 3 day course of 
ACT after switch  
 
 
0.77 
 
 
 
0.616 
 
 
 
 
0.3927 
 
 
 
[4] 
 
 
 
= covi1*adhab  
or covi2*adhvg or 
covi3*adhab 
 
 
=covab*psab*adhab 
 
 
 
 
Duration of intervention and drug availability 
dur1 = dur2 
 = dur3 
Total duration of MDA or MSAT 
 
0 years – long term Expert opinion 
 
ni2 
 
 
durτ1  
= durτ2 
 = durτ3 
 
Number of times per year MSAT with 
atovaquone/proguanil is carried out 
 
Duration of each pulse of MDA or MSAT 
 
 
1-4 years
-1
 
 
 
0.25 years  
 
Expert opinion  
 
 
Expert opinion 
 
dura 
 
Duration of availability of artemisinin 
 
0 years or long-term 
 
Expert opinion 
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monotherapy 
 
durab Duration of availability of ACT 
 
0 years or long-term Expert opinion 
durbn Duration of effectiveness of bed nets 0 or 4 years Expert opinion 
 
Drug pharmacodynamics 
  
Duration of efficacy against sensitive parasites (X ) 
Xao   Full course of artemisinin monotherapy 
 
7 days [16] 
Xai Dihydroartemisinin as part of ACT (3 day 
course) 
 
3 days [16] 
Xb Piperaquine  
 
20-30 days [17] 
Xv Atovaquone (as 3 days 
atovaquone/proguanil) 
 
10-15 days [18] 
Xg Proguanil (as 3 days atovaquone/proguanil) 
 
4 days [19] 
Xp Primaquine (1 day course) 1 day [20] 
  
Rates of clearance of drug sensitive infection (ν ) by treatment 
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cBroda Artemisinin vs noninfectious blood stage 
 
1/7 days
-1
 [21] 
cIroda Artemisinin vs infectious blood stage 
 
1/4days
-1
 Unpublished data 
from Lee S 
cBrodb Piperaquine vs noninfectious blood stage 
 
1/3 days
-1
 [22] 
cIrodb Piperaquine vs infectious blood stage 
 
1/21 days
-1
 [22] 
crodab ACT vs any stage 
 
1/7 days
-1
 (no synergy 
assumed) –  
1/3 days
-1
 (synergy 
assumed) 
 
[21,23,24] 
cLdvg Atovaquone/proguanil vs liver stage 
 
1/3 days
-1
 [25] 
cBdvg Atovaquone/proguanil vs non-infectious 
blood stage 
 
1/3 days
-1
 [18] 
cIdvg = cIdv Atovaquone/proguanil vs infectious blood 
stage= atovaquone vs infectious blood 
stage 
 
1/(4.5) days
-1
 Unpublished data 
from Lee S 
cLdv Atovaquone vs liver stage 
 
1/6 days
-1
 [25] 
cBdv Atovaquone vs non-infectious blood stage 1/3 days
-1
 [18] 
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infection 
 
cLdp Primaquine vs liver stage infection 
 
1/7days
-1
 [18] 
cIdp Primaquine vs infectious blood stage 
infection 
1/1 days
-1
 [20,26] 
  
Effect of drug resistance on pharmacodynamics 
As this is unknown, it was a modeled by multiplying the clearance rate for each drug by its 
relative effectiveness against resistant infections, ε, such that 0 ≤ ε ≤ 1. 
pctroda Parasite clearance time for artemisinin vs 
sensitive infections 
 
30 hours [27] 
pctrada Parasite clearance time for artemisinin vs 
resistant infections 
 
83 hours [28] 
precra Proportion of infections resistant to 
artemisinin that recrudesce after treatment 
with artemisinin monotherapy 
 
0.35 [28] 
εrada Relative effectiveness of artemisinin against 
artemisinin resistant parasites 
 
0.27 = pctroda/pctrada*(1 
-precra) 
εrbdb Relative effectiveness of piperaquine 
against resistant parasites 
0.8 [22] 
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cost 
 
 
Fitness cost of drug resistance 
This was modeled by multiplying the transmission parameter β by (1-cost) [29] for each 
drug: 
costa Artemisinin 
 
0 - 0.1 [2] 
costb Piperaquine 0 - 0.1 [2] 
 
Effectiveness of bednets 
ρ  Degree of transmission reduction (the 
product of coverage and efficacy) 
0.3 [30,31] 
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